Choreoacanthocytosis
koh-ree-oh-ah-kan-tho-sy-TOH-sis
Also known as: VPS13A Disease, Levine-Critchley Syndrome
At a Glance
What is Choreoacanthocytosis?
Choreoacanthocytosis is a rare genetic disorder that primarily affects the nervous system and blood cells. It is caused by mutations in the VPS13A gene, leading to abnormal protein function. The condition typically begins in early adulthood, with symptoms gradually worsening over time. Early symptoms often include involuntary movements, muscle weakness, and cognitive decline. As the disease progresses, individuals may experience difficulty speaking, swallowing, and walking. Early diagnosis is crucial for managing symptoms and improving quality of life. The disorder can have a significant impact on family life, requiring long-term care and support. Prognosis varies, but the condition is progressive and can lead to severe disability. Daily life for affected individuals often involves managing complex symptoms and adapting to physical limitations. Supportive therapies and interventions can help maintain function and independence. Research is ongoing to better understand the disease and develop targeted treatments.
Medical Definition
Choreoacanthocytosis is a neurodegenerative disorder characterized by the presence of acanthocytes in the blood and chorea. Pathologically, it involves degeneration of the basal ganglia and other brain regions. Histologically, there is neuronal loss and gliosis in affected areas. It is classified under neuroacanthocytosis syndromes. Epidemiologically, it is an ultra-rare condition with autosomal recessive inheritance. The disease course is progressive, leading to significant neurological and functional impairment over time.
Choreoacanthocytosis Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Chorea manifests as involuntary, irregular, and unpredictable movements that can affect any part of the body. It is caused by dysfunction in the basal ganglia, a brain region involved in movement control, due to mutations in the VPS13A gene. Over time, these movements can become more pronounced and interfere with voluntary actions. Patients often struggle with daily tasks such as eating and dressing, but physical therapy and medications like tetrabenazine can help manage symptoms.
Acanthocytosis is characterized by the presence of abnormally shaped red blood cells, known as acanthocytes, in the bloodstream. This occurs due to altered lipid composition in the cell membrane, influenced by the VPS13A gene mutation. The condition may progress slowly and can lead to mild anemia. Regular monitoring of blood parameters and supportive care can help manage potential complications.
Cognitive decline in choreoacanthocytosis often presents as difficulties with memory, attention, and executive functions. This is linked to the degeneration of neural pathways in the frontal-subcortical circuits. The decline is progressive, potentially leading to dementia over time. Cognitive rehabilitation and medications like donepezil may provide some benefit in managing these symptoms.
Common
Seizures in choreoacanthocytosis can range from mild to severe and may include convulsions or loss of consciousness. They are thought to result from abnormal electrical activity in the brain due to neuronal degeneration. Seizures may become more frequent as the disease progresses. Antiepileptic drugs can be effective in controlling seizure activity and improving quality of life.
Dysarthria manifests as slurred or slow speech that can be difficult to understand. It is caused by impaired control of the muscles used in speech, due to neurological damage. Over time, this symptom may worsen, affecting communication significantly. Speech therapy can help improve articulation and communication skills.
Muscle weakness in choreoacanthocytosis is often generalized and can affect both proximal and distal muscles. It results from a combination of neurodegeneration and muscle atrophy. The weakness tends to progress gradually, impacting mobility and daily activities. Physical therapy and occupational therapy can aid in maintaining muscle strength and function.
Less Common
Behavioral changes may include irritability, depression, and impulsivity. These changes are associated with frontal lobe dysfunction and psychiatric manifestations of the disease. They can fluctuate in severity and may contribute to social and occupational difficulties. Psychological support and medications like antidepressants can help manage these symptoms.
Dysphagia, or difficulty swallowing, can occur due to impaired coordination of the muscles involved in swallowing. This is linked to the neurological impact of the disease on motor control. As the condition progresses, dysphagia may lead to nutritional deficiencies and aspiration risks. Dietary modifications and swallowing therapy can assist in managing this symptom.
What Causes Choreoacanthocytosis?
Choreoacanthocytosis is primarily caused by mutations in the VPS13A gene, located on chromosome 9q21.2. The VPS13A gene encodes a protein called chorein, which is involved in intracellular trafficking and membrane maintenance. Mutations in VPS13A can lead to truncated or misfolded chorein, disrupting its normal function. This disruption impairs the transport of proteins and lipids between organelles, particularly affecting the endosomal and lysosomal pathways. As a result, there is an accumulation of dysfunctional organelles and altered cellular homeostasis. Neighboring neurons and glial cells experience increased oxidative stress and metabolic imbalances. Neuroinflammation is often triggered as the immune system responds to cellular debris and stress signals. Over time, this leads to degeneration of white matter and basal ganglia structures, which are crucial for motor control. The specific pattern of symptoms, such as chorea and cognitive decline, arises from the selective vulnerability of these brain regions. Variability in disease severity among patients can be attributed to the presence of modifier genes and environmental factors. Additionally, the progression of neurodegeneration can vary based on the extent of immune response and compensatory mechanisms in the brain. The interplay between genetic mutations and cellular stress responses contributes to the heterogeneity of clinical presentations. Understanding these molecular and cellular processes is essential for developing targeted therapies for choreoacanthocytosis.
How is Choreoacanthocytosis Diagnosed?
Typical age of diagnosis: Choreoacanthocytosis is typically diagnosed in early adulthood, often between the ages of 20 and 40, when neurological symptoms become prominent. Diagnosis may be delayed due to the rarity of the condition and its overlap with other movement disorders.
Clinicians look for characteristic movement disorders such as chorea, dystonia, and tics. A detailed family history is crucial, as choreoacanthocytosis is inherited in an autosomal recessive manner. Physical examination may reveal orofacial dyskinesias and limb chorea. This step helps to differentiate choreoacanthocytosis from other neurodegenerative disorders.
Magnetic Resonance Imaging (MRI) is the preferred modality to assess brain structure. Specific abnormalities such as atrophy of the caudate nucleus and putamen are often visible. These findings support the diagnosis by correlating with the clinical picture. Imaging helps exclude other causes of movement disorders, such as Huntington's disease.
Blood tests are ordered to evaluate for acanthocytosis, which is the presence of spiculated red blood cells. Elevated creatine kinase levels may also be observed. Abnormal results, such as the presence of acanthocytes, guide the clinician towards a diagnosis of choreoacanthocytosis. These results prompt further genetic testing to confirm the diagnosis.
Genetic testing focuses on sequencing the VPS13A gene. Mutations such as deletions, insertions, or point mutations in VPS13A confirm the diagnosis. Identifying these mutations provides a definitive diagnosis and aids in genetic counseling for the family. This information is crucial for advising family members about carrier status and potential risks for offspring.
Choreoacanthocytosis Treatment Options
Tetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor. It works by depleting monoamines such as dopamine, which helps reduce chorea. Specific drugs used include tetrabenazine and deutetrabenazine. Clinical evidence shows efficacy in reducing involuntary movements, but side effects such as depression and parkinsonism may limit use. Close monitoring for psychiatric side effects is necessary.
Techniques include balance training, gait exercises, and coordination drills. The goal is to improve motor control and reduce fall risk. Sessions are typically conducted 2-3 times per week for 30-60 minutes. Measurable outcomes include improved balance scores and reduced fall frequency. Long-term benefits include enhanced quality of life and maintained independence.
Indicated for severe, medication-refractory chorea. The procedure involves implanting electrodes in the globus pallidus or subthalamic nucleus. Expected benefits include significant reduction in chorea and improved motor function. Surgical risks include infection, hemorrhage, and device malfunction. Post-operative care involves regular follow-up for device programming and monitoring.
The team includes neurologists, psychiatrists, physical therapists, and social workers. Interventions focus on symptom management, mental health support, and daily living assistance. Psychosocial support strategies include counseling and support groups. Family education covers disease progression and care strategies. Long-term monitoring involves regular assessments and adjustments to the care plan.
When to See a Doctor for Choreoacanthocytosis
- Sudden onset of severe involuntary movements — this may indicate an acute exacerbation requiring immediate medical attention.
- Loss of consciousness or severe confusion — these symptoms could suggest a neurological emergency.
- Difficulty breathing or swallowing — these can be life-threatening and require urgent evaluation.
- Progressive worsening of chorea — indicates disease progression and needs timely medical review.
- New onset of psychiatric symptoms — these could complicate the condition and require specialist intervention.
- Significant weight loss or nutritional deficiencies — may indicate feeding difficulties and need dietary management.
- Mild involuntary movements — monitor for changes in frequency or severity and discuss with a doctor during routine visits.
- Occasional mood swings — track any patterns and discuss with a healthcare provider if they worsen.
Choreoacanthocytosis — Frequently Asked Questions
Is this condition hereditary?
Choreoacanthocytosis is inherited in an autosomal recessive pattern, meaning both copies of the VPS13A gene in each cell have mutations. If both parents are carriers, there is a 25% chance of passing the condition to their children. De novo mutations are not typically seen in this condition. Carrier status does not usually result in symptoms, but genetic counseling is recommended for family planning. Genetic counseling can provide information on carrier testing and reproductive options.
What is the life expectancy for someone with this condition?
Life expectancy can vary, with earlier onset generally associated with a more severe course. Complications such as infections, nutritional deficiencies, and respiratory issues can worsen outcomes. Mortality is often due to complications like pneumonia or cardiac issues. While treatments can manage symptoms, they do not significantly extend life expectancy. Realistic expectations include a focus on quality of life and symptom management.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves clinical evaluation, blood tests, and genetic testing to confirm VPS13A mutations. The time from first symptoms to diagnosis can vary, often taking several years due to symptom overlap with other conditions. Neurologists and hematologists are typically consulted. Delayed diagnosis is common due to the rarity and complexity of symptoms. Confirmation is achieved through genetic testing, which identifies mutations in the VPS13A gene.
Are there any new treatments or clinical trials available?
Current research is exploring gene therapy and novel pharmacological approaches. Gene therapy aims to correct the underlying genetic defect, showing promise in preclinical studies. ClinicalTrials.gov is a resource for finding ongoing trials, and discussing options with your doctor is crucial. It is important to ask about eligibility and potential benefits or risks of participation. New treatments may take years to become widely available, but ongoing research is promising.
How does this condition affect daily life and activities?
Choreoacanthocytosis can significantly impact mobility, making self-care and daily activities challenging. Educational support may be necessary due to cognitive and motor difficulties. Social and emotional challenges include isolation and mood disorders, affecting both patients and families. The condition places a considerable burden on families, requiring adaptations and support. Occupational therapy, assistive devices, and support groups can help manage daily life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Choreoacanthocytosis. Clues to clinical diagnosis.
Sakai T, Mawatari S, Iwashita H et al. · Arch Neurol · 1981 · PMID: 6453575
- 2.Choreoacanthocytosis.
Anand IS, Khwaja GA, Gupta M · J Assoc Physicians India · 1994 · PMID: 7852238
- 3.VPS13A Disease.
Adam MP, Bick S, Mirzaa GM et al. · Unknown Journal · 1993 · PMID: 20301561
- 4.[Choreoacanthocytosis. A neurologic-hematologic syndrome].
Hiersemenzel LP, Johannes S, Themann P et al. · Nervenarzt · 1996 · PMID: 8767204
- 5.Frontal-subcortical dementias.
Bonelli RM, Cummings JL · Neurologist · 2008 · PMID: 18332839
- 6.Exome sequencing of choreoacanthocytosis reveals novel mutations in VPS13A and co-mutation in modifier gene(s).
Chaudhari S, Ware AP, Jasti DB et al. · Mol Genet Genomics · 2023 · PMID: 37209156
- 7.Diagnostic tests for choreoacanthocytosis.
Feinberg TE, Cianci CD, Morrow JS et al. · Neurology · 1991 · PMID: 1829792
- 8.Choreoacanthocytosis in a Mexican family.
Ruiz-Sandoval JL, García-Navarro V, Chiquete E et al. · Arch Neurol · 2007 · PMID: 17998451
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-15